Psychedelic Spotlight News

4 NEW Psychedelics Trial Updates in 1 Day | Psilocybin, LSD, 18MC + Microdosing [MNMD, CMPS, FH]

January 7, 2022June 2, 2024 Learn, Videos

Whether or not psychedelic medicines will become legalized to treat patients with mental health conditions will ultimately rest on whether clinical trials treating conditions with compounds like psilocybin are successful.

This is why today’s news is so exciting. We got updates on four separate clinical trials.
First, is new data from a phase 1 clinical trial using Compass Pathways (Nasdaq: CMPS) Comp360 psilocybin. This trial added to the growing data showing that large doses of psilocybin are safe to take. It also showed no negative cognitive side effects of taking the drug.

Next, we got updates on two MindMed (Nasdaq: MNMD, NEO: MMED) trials. First, we found out about a new phase 1 trial which will combine LSD with SSRIs. This will be important, because we need to know whether mental health patients with disorders like major depressive disorder can remain on their prescriptions when undergoing psychedelic therapy.

Next, MindMed announced that their phase 1 clinical trial attempting to treat addiction with 18-MC, a proprietary non-hallucinogenic version of ibogaine, was completed. We should expect data relatively soon, and a phase 2a trial to begin shortly after.

Finally, we learned of a new microdosing trial that is set to begin at the University of Toronto. This phase 2 trial will test treating persistent depressive disorder using psilocybin microdoses. The psilocybin is Filament Health’s (OTCQB:FLHLF, NEO:FH) version of psilocybin, making it an important step for this company.

For investors in psychedelic stocks, and those who just want to see better mental health care treatments alike, this was a big week. Hopefully, as time progresses, we will start getting data back from these trials and the shroom boom will go into full force!

Can psychedelics treat mental health conditions? Can microdosing help depression? Can you keep taking antidepressants while taking LSD? Today, we became a step closer to answering all of these questions!

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
@Psychedelic Spotlight

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Microdosing #Psilocybin

Psychedelics Can Change Your View on the Nature of Reality

January 6, 2022June 2, 2024 Learn, Research

A recent study has found that psychedelics can fundamentally change your core beliefs about the nature of fate, reality, and consciousness.

Psychedelics Will Have a Big Presence at SXSW in 2022

January 5, 2022June 2, 2024 Culture, Learn

Tim Ferriss and Roland Griffiths are among the biggest names in the burgeoning psychedelics movement that are set to appear during the SXSW Conference running from March 11-20.

Mindset Pharma Teams Up with The McQuade Center to Develop 2 Families of Novel Psychedelic Compounds

January 5, 2022June 2, 2024 Business, Learn

It’s yet another sign that the pharmaceutical industry at large is taking the potential of psychedelics very seriously.

Health Canada Grants Special Access to Restricted Drugs for Psychedelic Therapy

January 4, 2022June 2, 2024 Act, Policy

New amendment reverses a 2013 Health Canada policy that prevented “a letter of authorization for a new drug that is or that contains a restricted drug.”

5 Ways ‘The Matrix Resurrections’ Is More Psychedelic Than the Original Trilogy

December 31, 2021June 2, 2024 Culture, Learn

“The Matrix” was always an allegory for awakening to your full potential, and the fourth sequel creates the proper set and setting to dive even further through the looking glass.

Psychedelic Business Spotlight – December 31

December 31, 2021June 2, 2024 Business, Learn, Stock Reports

This week in psychedelic business news: Mindset Pharma files another patent for compounds with “perfect microdosing drug profile,” and Core One Labs is preparing to capitalize on functional mushroom market.

Did Canada Just Quietly Legalize Psychedelic Therapy? Kind of, but it’s Complicated

December 31, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

Did Canada just legalize Psychedelic therapy? Psychedelic therapies, such as…

2021: A Year in Review for the Psychedelics Business

December 30, 2021June 2, 2024 Business, Learn

Our resident Psychedelic Investor looks back at some of this growing industry’s biggest moments and how they may shape the business in 2022.

Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More

December 30, 2021June 2, 2024 Listen, Videos

The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?

Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.

The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.

The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.

Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.

And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.

Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.